KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Current Deferred Revenue (2016 - 2022)

Bio-Rad Laboratories (BIO) has disclosed Current Deferred Revenue for 13 consecutive years, with $52.2 million as the latest value for Q4 2022.

  • On a quarterly basis, Current Deferred Revenue rose 2.58% to $52.2 million in Q4 2022 year-over-year; TTM through Dec 2022 was $52.2 million, a 2.58% increase, with the full-year FY2022 number at $52.2 million, up 2.58% from a year prior.
  • Current Deferred Revenue was $52.2 million for Q4 2022 at Bio-Rad Laboratories, up from $50.9 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $60.0 million in Q4 2020 to a low of $37.3 million in Q4 2018.
  • A 5-year average of $46.0 million and a median of $45.6 million in 2019 define the central range for Current Deferred Revenue.
  • Peak YoY movement for Current Deferred Revenue: soared 31.0% in 2020, then dropped 15.17% in 2021.
  • Bio-Rad Laboratories' Current Deferred Revenue stood at $37.3 million in 2018, then increased by 22.79% to $45.8 million in 2019, then skyrocketed by 31.0% to $60.0 million in 2020, then fell by 15.17% to $50.9 million in 2021, then grew by 2.58% to $52.2 million in 2022.
  • Per Business Quant, the three most recent readings for BIO's Current Deferred Revenue are $52.2 million (Q4 2022), $50.9 million (Q4 2021), and $60.0 million (Q4 2020).